Research on apolipoprotein B is advancing, with studies exploring its structure and role in atherogenic lipoproteins, as well as its connection to cardiovascular disease risk. New guidelines and clinical trials are being developed to improve the management of dyslipidemia and heart disease risk assessment, potentially leading to more effective treatments. The field is also seeing the emergence of new cholesterol drugs and testing methods that may better predict heart disease risk.